Table 1.
Correlation of high XB130 expression with clinicopathological parameters
| XB130 expression | ||||
|---|---|---|---|---|
|
|
||||
| Characteristics | No. of patients | Positive (%) | Negative (%) | P-value |
| Age (years) | NS | |||
| ≤50 | 57 | 31 (54.4) | 26 (45.6) | |
| >50 | 83 | 56 (67.5) | 27 (32.5) | |
| Tumor size (cm) | NS | |||
| ≤2 | 36 | 19 (52.8) | 17 (47.2) | |
| >2 | 104 | 68 (65.4) | 36 (34.6) | |
| Tumor classification | 0.024 | |||
| T1-T2 | 119 | 71 (59.7) | 48 (40.3) | |
| T3-T4 | 21 | 16 (76.2) | 5 (23.8) | |
| Clinical stage | 0.0084 | |||
| I-II | 96 | 48 (50) | 48 (50) | |
| III-IV | 44 | 39 (88.6) | 5 (11.4) | |
| Lymph node status | 0.0013 | |||
| Positive | 68 | 56 (82.3) | 12 (17.7) | |
| Negative | 72 | 31 (43) | 41 (57) | |
| ER status | NS | |||
| Positive | 96 | 56 (58.3) | 40 (41.7) | |
| Negative | 44 | 31 (70.4) | 13 (29.6) | |
| PR status | NS | |||
| Positive | 95 | 58 (61) | 37 (39) | |
| Negative | 45 | 29 (64.4) | 16 (35.6) | |
| Her-2 status | NS | |||
| Positive | 33 | 21 (63.6) | 12 (36.4) | |
| Negative | 107 | 66 (61.7) | 41 (38.3) | |
| Menopausal | NS | |||
| Pre-menopausal | 73 | 43 (58.9) | 30 (41.1) | |
| Post-menopausal | 67 | 44 (65.7) | 23 (34.3) | |
NS: statistical significance.